MedTrace Logo

IMC001 for Clinical Research on Advanced Digestive System Malignancies

NCT05028933 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-02-12

No results posted yet for this study

Summary

A Phase I Clinical Study of Autologous T cells modified with chimeric antigen receptor targeting EpCAM ( EPCAM CAR-T) in Patients with malignant tumors of the digestive system (including advanced gastric cancer, colorectal cancer, liver cancer and pancreatic cancer) .

Conditions

Interventions

DRUG

EPCAM CAR-T

Pretreatment with fludarabine and cyclophosphamide EpCAM CAR-T Cells infusion

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Principal Investigators

  • Weijia Fang · The First Affiliated Hospital, Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2024-12-30
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05028933 on ClinicalTrials.gov